@article {1812, title = {Potential Roles of Purslane (Portulaca oleracea L.) as Antimetabolic Syndrome: A Review}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {June 2022}, pages = {710-714}, type = {Review Article}, chapter = {710}, abstract = {

The number of cases of obesity and type 2 diabetes mellitus (T2DM) is part of the metabolic syndrome case. Purslane (Portulaca oleracea L.) is a plant that has been clinically tested and has the potential to prevent and treat metabolic syndrome as well as pathogenic and pathophysiological activities that cause disease. The aim of this study is to discuss and conclude information regarding the activity and use of purslane (P. oleracea) as an antimetabolic. This review article is based on scientific publications found on Google Scholar and PubMed databases using the keywords of {\textquotedblleft}Portulaca obesity{\textquotedblright}, {\textquotedblleft}Portulaca overweight{\textquotedblright}, {\textquotedblleft}Portulaca dyslipidemia{\textquotedblright}, and {\textquotedblleft}Portulaca metabolic syndrome{\textquotedblright}. This plant acts on numerous pathways in the metabolic syndrome such as reduction of lipids, blood sugar, body weight and total cholesterol. Purslane (P. oleracea) can be used as a candidate for a new herbal plant as an anti-metabolic syndrome.

}, keywords = {Body weight, Insulin resistance, Metabolic syndrome, Obesity., Portulaca oleracea}, doi = {10.5530/pj.2022.14.90}, author = {Nur Sofiatul Aini and Arif Nur Muhammad Ansori and Viol Dhea Kharisma and Muhammad Farraz Syadzha and Muhammad Hermawan Widyananda and Ahmad Affan Ali Murtadlo and Rasyadan Taufiq Probojati and Md. Emdad Ullah and Sin War Naw and Vikash Jakhmola and Rahadian Zainul} } @article {1704, title = {Alterations in Body Weight, Blood Glucose Levels, and Lipid Profiles in High-Fat Diet-Low Dose Streptozotocin-Induced Diabetic Rats}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {December 2021}, pages = {1562-1567}, type = {Original Article}, chapter = {1562}, abstract = {

Introduction: New preventive and therapeutic strategies to treat Type 2 diabetes (T2D) continue to be pursued, the complexity of this disease makes it imperative to establish preclinical animal models which must provide accurate similarities to the pathogenesis of diabetes in humans. Making a diabetic animal model using rats with high-fat diet (HFD)-streptozotocin (STZ) induction is popular because it is relatively low cost and simple. Objectives: This study aims to analyse the changes in body weight, blood glucose, and lipid profiles that occur in diabetic rat models created by induction of HFD in combination with lowdose STZ. Methods: This study used forty male Sprague-Dawley rats (200-240 g). After the adaptation period, thirty rats were fed with HFD for 28 days (DM group), while the other ten rats continued to be fed with standard feed (NC group). After then, diabetes was induced to the DM group by low-dose STZ (35 mg/kg BW). The body weight of the rats was measured before and after diet manipulation periods. Blood samples were taken before and after STZ induction to determine lipid profiles and blood glucose levels. Results: During the diet manipulation period, the HFD group experienced a significantly greater weight gain, higher blood glucose levels, and cholesterol (TC) levels. After STZ injection, rats{\textquoteright} blood glucose levels, TC, and triglycerides significantly increased. Conclusion: HFD feeding combined with a low-dose STZ effectively work to mimic specific condition that is similar to T2D, and the stability of the experimental animal conditions remains constant for up to 6 weeks.

}, keywords = {Diabetes, Diabetic animal model, High-fat diet, Insulin resistance, Low-dose streptozotocin, Stable diabetes type 2 profile.}, doi = {10.5530/pj.2021.13.199}, author = {Raysa Y. Pratiwi and Berna Elya and Heri Setiawan and Atini Solawati and Rosmalena} } @article {1413, title = {Effect of Soybean on Bone Health and Some Metabolic Parameters in Postmenopausal Egyptian Women}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {May 2021}, pages = {688-697}, type = {Original Article}, chapter = {688}, abstract = {

Introduction: Great concern has been raised recently concerning the therapeutic impact of soybean. The present study aims to investigate the effects of soybean on bone health and metabolic parameters in postmenopausal women. Methods: In this clinical study, 72 healthy postmenopausal women aged between 45-65 years were given soybean bioactive fraction 2 capsules (500mg each) daily for 24 weeks. Each capsule contained 31.25 mg proteins, 3.2 mg carbohydrates and 4.84 mg isoflavones. Blood pressure, bone mineral density, plasma osteocalcin (OCN), telopeptides of collagen type I (CTX), fasting insulin and blood glucose, lipid profile, serum creatinine, alanine transaminase (ALT), aspartate transaminase (AST), and TSH were assessed prior and after the period of the study. Insulin resistance was calculated by homeostatic model assessment-IR formula (HOMA-IR). Results: Soy ingestion resulted in a significant increase in T score of the hip and OCN; recording -1.97{\textpm}0.13/-1.76{\textpm}0.12 and 22.44{\textpm}0.60ng/ml/30.93{\textpm}0.57ng/ml before/after treatment, respectively. A marked decrease was also detected in CTX from 2.22{\textpm}0.10ng/ml to 1.48{\textpm}0.08ng/ml. With regard to metabolic parameters, there was a significant decrease in fasting insulin (5.40{\textpm}0.62uU/ml vs 4.15{\textpm}0.45uU/ ml), however, fasting glucose and HOMA-IR showed no significant alterations. Lipid profile displayed remarkable decline in total cholesterol (188.86{\textpm}7.23mg/dl vs 159.60{\textpm}4.72mg/dl, triglycerides (97.09{\textpm}5.23mg/dl vs 83.56{\textpm}4.27mg/dl), LDL-c (75.60{\textpm}3.06mg/dl vs 63.95{\textpm}1.86mg/ dl) accompanied with a significant elevation in HDL-c (53.09{\textpm}0.88 vs 65.81mg/dl{\textpm}0.80mg/ dl). A significant decrease in both TSH (1.97{\textpm}0.13 uIU/ml vs 1.40{\textpm}0.08 uIU/ml) and serum creatinine (0.82{\textpm}0.02mg/dl vs0.77{\textpm}0.02mg/dl) was also noticed. Conclusion: Consumption of soy improves bone health, reduces cardiovascular risk with no adverse effects on kidney, liver or thyroid functions.

}, keywords = {Bone health, Bone mineral density, Hypocholesterolemic effect, Insulin resistance, Metabolic parameters, Soybean}, doi = {10.5530/pj.2021.13.88}, author = {Mouchira Abdel Salam and Hala M. Raslan and Doha A. Mohamed and Aliaa Elgendy and Rehab A. Hussein and Omneya Moguib and Maha Abdelhadi and Rokia Abd El-Shafy Soliman El-Banna and Karem Fouda and Safenaz Y. El Sherity and Emad N. Zikri and Nagwa M. Ammar} }